Regenxbio (RGNX) delivered earnings and revenue surprises of -7.81% and 37.77%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
The threat is still emerging, but it could be significant.
Data from an early-stage study shows that treatment with REGENXBIO's (RGNX) investigational Duchenne therapy RGX-202 demonstrates early evidence of strength and motor function improvement.